PCSK9 Inhibitors Added to Moderate/High-Intensity Statin Therapy Are Associated With Improved Liver-Related Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (ACG 2026) - Aug 29, 2026 - Abstract #P6078; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "We compared patients who initiated a PCSK9 inhibitor (alirocumab, evolocumab, or inclisiran) at least 3 months after MASLD diagnosis (n=10,940) versus those on M/HI statins alone (n=604,717). After PSM, 10,216 patients per group were identified (Table 1). Median follow-up was 516 vs. 485 days."
Clinical • CNS Disorders • Dyslipidemia • Familial Hypercholesterolemia • Fibrosis • Gastroenterology • Genetic Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor
|
|
Ludovic Saba MD MSc 1; Michel Toutoungy MD 1; Wissam Ghusn MD 2; Lisa B.. VanWagner MD MSc 1
|